Knockdown of SLC35F2 Inhibits the Proliferation and Metastasis of Bladder Cancer Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Dec 19

PMID 31849485

Citations 5

Authors

Mei Chen

Xin Gao

Denggao Huang

Shunlan Wang

Linlin Zheng

Yinyi Chen

Xiaohong Wen

Yuanhui Gao

Hui Cao

Shufang Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Many studies have shown that solute carrier family 35 member F2 (SLC35F2) plays a key role in the biological processes of multiple cancers. However, there have been no reports on the role of SLC35F2 in the occurrence and development of bladder cancer (BC).

Methods: SLC35F2 expression data and clinical and prognostic information from BC patients were obtained from databases. SLC35F2 expression in BC was verified by quantitative real-time PCR (qRT-PCR). The influence of SLC35F2 knockdown on the proliferation, apoptosis, migration and invasion in the 5637 and T24 cell lines was studied, and tumor formation experiments were performed in nude mice. Gene set enrichment analysis (GSEA) was used to predict the pathways and functions of SLC35F2 in BC.

Results: SLC35F2 was highly expressed in BC tissues and was associated with invasiveness and T stage in BC patients. SLC35F2 knockdown can inhibit the proliferation, migration and invasion of BC cells and can promote apoptosis. SLC35F2 knockdown significantly reduced tumorigenesis in nude mice. GSEA showed that BC, pathways in cancer, apoptosis and the P53 signaling pathway were significantly enriched in SLC35F2 high expression phenotype.

Conclusion: SLC35F2 can promote malignant progression and is a potential therapeutic target in BC.

Citing Articles

Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.

Chen M, Nie Z, Huang D, Gao Y, Cao H, Zheng L Front Immunol. 2022; 13:1048204.

PMID: 36505496 PMC: 9732944. DOI: 10.3389/fimmu.2022.1048204.

Solute Carrier Family 35 Member F2 Regulates Cisplatin Resistance and Promotes Malignant Progression of Pancreatic Cancer by Regulating RNA Binding Motif Protein 14.

Zhang S, Li Q, Yuan H, Ren L, Liang X, Li S J Oncol. 2022; 2022:5091154.

PMID: 35669242 PMC: 9166975. DOI: 10.1155/2022/5091154.

USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2.

Chandrasekaran A, Kaushal K, Park C, Kim K, Ramakrishna S Theranostics. 2021; 11(20):9752-9771.

PMID: 34815782 PMC: 8581437. DOI: 10.7150/thno.63806.

RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt Pathway.

Han C, Chen S, Ma H, Wen X, Wang Z, Xu Y Onco Targets Ther. 2021; 14:1643-1657.

PMID: 33727825 PMC: 7953128. DOI: 10.2147/OTT.S300480.

SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells.

Kotolloshi R, Holzer M, Gajda M, Grimm M, Steinbach D Cells. 2021; 10(1).

PMID: 33418944 PMC: 7825079. DOI: 10.3390/cells10010080.

References

Nyquist M, Corella A, Burns J, Coleman I, Gao S, Tharakan R . Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. Mol Cancer Res. 2017; 15(5):521-531. PMC: 5471626. DOI: 10.1158/1541-7786.MCR-16-0315-T. View

Zhu N, Hou J, Wu Y, Liu J, Li G, Zhao W . Integrated analysis of a competing endogenous RNA network reveals key lncRNAs as potential prognostic biomarkers for human bladder cancer. Medicine (Baltimore). 2018; 97(35):e11887. PMC: 6392549. DOI: 10.1097/MD.0000000000011887. View

Chen J, Song B, Kong G . MicroRNA‑663b downregulation inhibits proliferation and induces apoptosis in bladder cancer cells by targeting TUSC2. Mol Med Rep. 2019; 19(5):3896-3902. DOI: 10.3892/mmr.2019.10023. View

Zhang S, Yu L, Wang P, Kou P, Li J, Wang L . Inotodiol inhibits cells migration and invasion and induces apoptosis via p53-dependent pathway in HeLa cells. Phytomedicine. 2019; 60:152957. DOI: 10.1016/j.phymed.2019.152957. View

Meng L, Liu S, Ding P, Chang S, Sang M . Circular RNA ciRS-7 inhibits autophagy of ESCC cells by functioning as miR-1299 sponge to target EGFR signaling. J Cell Biochem. 2019; 121(2):1039-1049. DOI: 10.1002/jcb.29339. View

Xu C, Shao H, Liu S, Qin B, Sun X, Tian L . Possible regulation of genes associated with intracellular signaling cascade in rat liver regeneration. Scand J Gastroenterol. 2008; 44(4):462-70, 10 p following 470. PMC: 2657316. DOI: 10.1080/00365520802495560. View

Dong Y, Pang Z, Zhang J, Hu J, Wang L . Long non-coding RNA GClnc1 promotes progression of colorectal cancer by inhibiting p53 signaling pathway. Eur Rev Med Pharmacol Sci. 2019; 23(13):5705-5713. DOI: 10.26355/eurrev_201907_18308. View

Zhou S, Liang Y, Zhang X, Liao L, Yang Y, Ouyang W . SHARPIN Promotes Melanoma Progression via Rap1 Signaling Pathway. J Invest Dermatol. 2019; 140(2):395-403.e6. DOI: 10.1016/j.jid.2019.07.696. View

Bangsow T, Baumann E, Bangsow C, Jaeger M, Pelzer B, Gruhn P . The epithelial membrane protein 1 is a novel tight junction protein of the blood-brain barrier. J Cereb Blood Flow Metab. 2008; 28(6):1249-60. DOI: 10.1038/jcbfm.2008.19. View

10.

Nishimura M, Suzuki S, Satoh T, Naito S . Tissue-specific mRNA expression profiles of human solute carrier 35 transporters. Drug Metab Pharmacokinet. 2009; 24(1):91-9. DOI: 10.2133/dmpk.24.91. View

11.

Shang L, Wei M . Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway. Front Oncol. 2019; 9:306. PMC: 6498871. DOI: 10.3389/fonc.2019.00306. View

12.

Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A . International variations in bladder cancer incidence and mortality. Eur Urol. 2014; 66(1):59-73. DOI: 10.1016/j.eururo.2013.10.001. View

13.

Wang Z, Zhou Q, Li A, Huang W, Cai Z, Chen W . Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer. Onco Targets Ther. 2019; 12:1423-1432. PMC: 6389008. DOI: 10.2147/OTT.S191321. View

14.

Huang L, Cai C, Dang W, Lu J, Hu G, Gu J . Propyl isothiocyanate induces apoptosis in gastric cancer cells by oxidative stress via glutathione depletion. Oncol Lett. 2019; 18(5):5490-5498. PMC: 6781591. DOI: 10.3892/ol.2019.10875. View

15.

Sanchez I, Dynlacht B . New insights into cyclins, CDKs, and cell cycle control. Semin Cell Dev Biol. 2005; 16(3):311-21. DOI: 10.1016/j.semcdb.2005.02.007. View

16.

Leake I . Colorectal cancer. Understanding the routes of metastasis in colorectal cancer. Nat Rev Gastroenterol Hepatol. 2014; 11(5):270. DOI: 10.1038/nrgastro.2014.60. View

17.

Li J, Cheng Y, Qu W, Sun Y, Wang Z, Wang H . Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells. Basic Clin Pharmacol Toxicol. 2010; 108(2):84-93. DOI: 10.1111/j.1742-7843.2010.00613.x. View

18.

Gao H, Yu G, Zhang X, Yu S, Sun Y, Li Y . BZW2 gene knockdown induces cell growth inhibition, G1 arrest and apoptosis in muscle-invasive bladder cancers: A microarray pathway analysis. J Cell Mol Med. 2019; 23(6):3905-3915. PMC: 6533564. DOI: 10.1111/jcmm.14266. View

19.

Stankovic T, Byrd P, Cooper P, McConville C, Munroe D, Riley J . Construction of a transcription map around the gene for ataxia telangiectasia: identification of at least four novel genes. Genomics. 1997; 40(2):267-76. DOI: 10.1006/geno.1996.4595. View

20.

Bu L, Jiang G, Yang F, Liu J, Wang J . Highly expressed SLC35F2 in non-small cell lung cancer is associated with pathological staging. Mol Med Rep. 2011; 4(6):1289-93. DOI: 10.3892/mmr.2011.572. View